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Abstract
Nasopharyngeal carriage is a precursor for pneumococcal disease and can be useful for
evaluating pneumococcal conjugate vaccine (PCV) impact. We studied pre-PCV pneumo-
coccal carriage among HIV-infected and -uninfected children in Mozambique. Between
October 2012 and March 2013, we enrolled HIV-infected children age <5 years presenting
for routine care at seven HIV clinics in 3 sites, including Maputo (urban-south), Nampula
(urban-north), and Manhic¸a (rural-south). We also enrolled a random sample of HIV-unin-
fected children <5 years old from a demographic surveillance site in Manhic¸a. A single naso-
pharyngeal swab was obtained and cultured following enrichment in Todd Hewitt broth with
yeast extract and rabbit serum. Pneumococcal isolates were serotyped by Quellung reac-
tion and multiplex polymerase chain reaction. Factors associated with pneumococcal car-
riage were examined using logistic regression. Overall pneumococcal carriage prevalence
was 80.5% (585/727), with similar prevalences among HIV-infected (81.5%, 339/416) and
HIV-uninfected (79.1%, 246/311) children, and across age strata. Among HIV-infected,
after adjusting for recent antibiotic use and hospitalization, there was no significant associa-
tion between study site and colonization: Maputo (74.8%, 92/123), Nampula (83.7%, 82/
98), Manhic¸a (84.6%, 165/195). Among HIV-uninfected, report of having been born to an
HIV-infected mother was not associated with colonization. Among 601 pneumococcal iso-
lates from 585 children, serotypes 19F (13.5%), 23F (13.1%), 6A (9.2%), 6B (6.2%) and
19A (5.2%) were most common. The proportion of serotypes included in the 10- and 13-
valent vaccines was 44.9% and 61.7%, respectively, with no significant differences by HIV
status or age group. Overall 36.9% (n = 268) of children were colonized with a PCV10
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serotype and 49.7% (n = 361) with a PCV13 serotype. Pneumococcal carriage was com-
mon, with little variation by geographic region, age, or HIV status. PCV10 was introduced in
April 2013; ongoing carriage studies will examine the benefits of PCV10 among HIV-infected
and–uninfected children.
Introduction
Streptococcus pneumoniae is a leading cause of bacterial pneumonia, meningitis and sepsis
among children in developing countries[1]. An estimated 541,000 children less than 5 years of
age die of pneumococcal disease each year, and most of these children live in developing coun-
tries[2]. HIV-infected children are at particularly high risk for pneumococcal disease and mor-
tality[3, 4]. The high disease burden in developing countries, combined with limited access to
health services and obstacles to providing appropriate treatment, make vaccination against
pneumococcal disease a priority[5].
Pneumococcal conjugate vaccines (PCV) have been widely used in high-income countries
for more than a decade, resulting in a dramatic reduction in pneumococcal disease caused by
vaccine serotypes[6]. PCV has also been shown to protect against colonization with the sero-
types included in the vaccine, leading to reductions in carriage and hence transmission in the
community of vaccine serotypes[7–9]. Nasopharyngeal colonization with S. pneumoniae is a
precursor to invasive pneumococcal infection, and the prevalence of pneumococcal carriage is
very high among children, particularly in low-income countries where crowded living condi-
tions and suboptimal sanitation facilitate transmission[10, 11]. Although most people colo-
nized with S. pneumoniae do not develop invasive disease, examining pneumococcal carriage
among young children provides insight into the serotype distribution and antimicrobial resis-
tance of circulating strains. Nasopharyngeal carriage studies can also provide a baseline for
measuring the impact of PCV introduction[12].
Mozambique introduced a 10-valent PCV (PCV10) into the national routine infant immu-
nization schedule on April 2013. We conducted a cross-sectional nasopharyngeal carriage
study to characterize S. pneumoniae carriage among HIV-infected and -uninfected children
before PCV10 introduction and to determine whether carriage differed in urban and rural
settings.
Materials and methods
The study was carried out from October 2012 to March 2013 in three areas of Mozambique:
Manhic¸a district, a rural area in the south; Maputo, an urban area in the south; and Nampula,
an urban area in the north. We enrolled HIV-infected (all 3 sites) and HIV-uninfected (Man-
hic¸a only) children aged<5 years. HIV-infected children were defined as those with a positive
HIV PCR at any point or positive HIV rapid test (Unigold and Determine test) after 18 months
of age; they were recruited from pediatric outpatient HIV clinics in all study sites, including 4
clinics in Maputo, 3 in Nampula, and one in Manhic¸a. Study staff approached the parents/
guardians of all children presenting to the clinics to assess eligibility. Enrollment at clinics was
sequential until target enrollment numbers for each age group were achieved. HIV-uninfected
children were recruited from an existing Demographic Surveillance System (DSS) in Manhic¸a
District[13]. The DSS covers a population of approximately 92,000 people who are assigned
unique identifying numbers; households within the DSS are visited twice yearly to record
births, deaths, and migration. Morbidity surveillance is conducted at Manhic¸a District
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Hospital and several satellite clinics; data from healthcare facility visits and results of labora-
tory testing conducted at Manhic¸a District Hospital are linked by the DSS unique number. A
stratified random sample of children aged<5 years in the DSS was selected to ensure represen-
tation across age groups (<12 months, 12–23 months and 24–59 months). Community enroll-
ment in Manhic¸a was restricted to those children known to be HIV-uninfected or with
unknown HIV status; because clinicians in Manhic¸a have a low threshold for HIV testing for
children, those children with no history of HIV testing were assumed to be HIV-uninfected.
For both HIV-infected and -uninfected groups, children with any sign of serious illness at the
time of enrollment were excluded.
After obtaining signed informed consent from a parent or guardian, a standardized ques-
tionnaire was used to collect demographic and epidemiologic data on the study participants
and their households. Nasopharyngeal specimens were collected by trained study personnel
using sterile calcium alginate swabs (Fisherbrand; Fisher Scientific, Pittsburg, PA). The swabs
were immediately placed in 1.0 ml skim milk-tryptone-glucose-glycerol (STGG) medium and
kept on wet ice packs in a cooler box. Within 4 hours of collection, the nasopharyngeal speci-
mens in STGG were vortexed for 10 to 20 seconds to disperse the organisms from the swab,
and frozen at -70˚C. For isolation, frozen specimens underwent a brief complete thawing and
vigorous vortexing, then 200μl were transferred into specific broth enrichment (5.0 ml Todd
Hewitt broth containing 0.5% yeast extract [THY] and 1 ml of rabbit serum), and the mixture/
broth were incubated at 37C˚ in a CO2 incubator for 6 hours. A 10μl loop of cultured broth
was inoculated on tryptone soy agar plates with 5% sheep blood (BAP), incubated at 37C˚ in a
CO2 atmosphere and examined after 18–24 hours[14]. All suspected pneumococcal colonies
were tested by optochin susceptibility (BBL Taxo; Becton Dickinson) and bile solubility 2%
sodium deoxycholate (SIGMA-ALDRICH, Steinheim, Germany). When alpha-hemolytic col-
onies of more than one morphology were identified as possible S. pneumoniae, colonies of
each morphology were selected for further testing. Pneumococcal isolates were serotyped by
Quellung reaction. For non-typeable pneumococcal isolates, real time polymerase chain reac-
tion (PCR) was performed for pneumococcal lytA gene detection to confirm that the isolate
was S. pneumoniae; multiplex PCR for pneumococcal serotyping was performed for lytA-iso-
lates that were non-typeable by Quellung [14, 15].
Pneumococcal isolates from HIV-infected children were tested for susceptibility to com-
monly used antibiotics including penicillin, ceftriaxone, amoxicillin, erythromycin, chloram-
phenicol, rifampicin and trimethoprim/sulfamethoxazole using the broth microdilution
method. Isolates were classified as susceptible, intermediate or resistant according to the Clini-
cal and Laboratory Standards Institute guidelines[16]; for penicillin we used both the non-
meningitis parenteral breakpoints (2 μg/mL: susceptible; 4 μg/mL: intermediate;8 μg/mL:
resistant) and the non-meningitis oral breakpoints (0.06 μg/mL: susceptible; 0.12–1 μg/mL:
intermediate;2 μg/mL: resistant).
Statistical analysis was performed using STATA v.13 software program (StataCorp, College
Station, TX, USA) and SAS v 9.3 (Cary, NC, USA). Carriage prevalence estimates and 95%
confidence intervals were calculated using the binomial exact method. Association between
pneumococcal carriage and other factors was examined using univariate and multivariable
logistic regression. Pneumococcal vaccine serotypes were defined as those included in PCV10
(1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F) and PCV13 (PCV10 serotypes plus 3, 6A, and 19A);
non-vaccine serotypes were defined as those not included in PCV10 and PCV13. Isolates with
no serotype determined by Quelling and PCR were considered non-typeable.
The protocol was approved by the institutional review boards of the Mozambican Ministry
of Health and the Centers for Disease Control and Prevention. Informed written consent was
obtained from the parents or guardians of all participants.
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Results
A total of 727 children were enrolled during the study period, including 416 (57.2%) from
HIV clinics and 311 (42.8%) from the DSS area (Table 1). The prevalence of nasopharyngeal
carriage of S. pneumoniae was 80.5% (95% confidence interval [CI] 77.4–83.3%) overall, 81.5%
(95% CI 77.4–85.1) among HIV-infected children, and 79.1% (95% CI 74.2–83.5) among
HIV-uninfected children. Among HIV-uninfected children, pneumococcal carriage was simi-
lar among those whose mother reported being HIV infected during pregnancy (82.7%, 95% CI
69.7–91.8) and those whose mother was reportedly HIV-negative (79.8%, 95% CI 73.3–85.3).
Carriage prevalence was also consistent between 249 children with a documented negative
HIV test (78.7%, 95%CI 73.1–83.6) and 62 children assumed to be HIV-uninfected (80.7%,
95%CI 68.6–89.6)The similarity in colonization prevalence among HIV-infected and–unin-
fected children was consistent across age groups (Fig 1).
Among HIV-infected children, the prevalence of pneumococcal carriage was lower in
Maputo (74.8%) than in the other two sites (Table 1, 84.6% in Manhic¸a and 83.7% in Nam-
pula); however on multivariable analyses (Table 2), there was no significant association
between site and pneumococcal colonization. Hospitalization within the past 3 months
(adjusted odds ratio [aOR] 0.364, 95% CI 0.195, 0.681), and reported antibiotic use within the
past 3 weeks (aOR 0.472, 95% CI 0.224, 0.997) were significantly less common among
Table 1. Prevalence of pneumococcal carriage by HIV infection, HIV exposure, and site.
Variable Number tested Number with S pneumoniae detected Prevalence 95% Confidence interval
HIV status
Uninfected 311 246 79.1 74.2 to 83.5
Infected 416 339 81.5 77.4 to 85.1
HIV exposure, HIV-uninfected
Exposed 52 43 82.7 69.7 to 91.8
Unexposed 188 150 79.8 73.3 to 85.3
Site, HIV-infected
Manhica 195 165 84.6 78.8 to 89.4
Maputo 123 92 74.8 66.2 to 82.2
Nampula 98 82 83.7 74.8 to 90.4
Overall 727 585 80.5 77.4 to 83.3
 HIV exposure data reported by parent/guardian; missing for 72/311 (23%)
https://doi.org/10.1371/journal.pone.0191113.t001
Fig 1. Prevalence of pneumococcal colonization among HIV-infected (n = 416) and uninfected (n = 311) children aged<5 years in Mozambique, by age group.
Number at the base of the bar represents the number of children colonized within each strata.
https://doi.org/10.1371/journal.pone.0191113.g001
Pre-vaccine pneumococcal carriage among HIV-infected and –uninfected children in Mozambique
PLOS ONE | https://doi.org/10.1371/journal.pone.0191113 February 15, 2018 4 / 12
colonized children compared with those not colonized with S. pneumoniae. No risk factors for
pneumococcal colonization were identified.
A total of 601 pneumococcal isolates were obtained for serotyping, including isolates of 1
serotype from 569 children plus isolates of 2 different serotypes from each of 16 children.
Among 43 different serotypes identified, the most frequent were 19F (n = 81, 13.5%), 23F
(n = 79, 13.1%), 6A (n = 55, 9.2%), 6B (n = 37, 6.2%) and 19A (n = 31, 5.2%); 36 (6.0%) isolates
were non-typeable. Although some differences were noted in the distribution of serotype by
HIV status (Fig 2), only the prevalence of 18C was found to be significantly different (0%
among HIV-infected vs. 2.0% among HIV-uninfected; p = 0.014).
Among 601 isolates, 44.9% (n = 270) were serotypes included in PCV10, and 61.7%
(n = 371) were serotypes included in PCV13. Among all 727 children, 36.9% (n = 268) were
Table 2. Factors associated with pneumococcal colonization among HIV-infected and–uninfected children aged<5 years in Mozambique.
Characteristic HIV-infected HIV-uninfected
Colonized
(n = 339)
n (%)
Not colonized
(n = 77)
n (%)
Crude odds ratio (95%
confidence interval)
Adjusted odds ratio
(95% confidence
interval)
Colonized
(n = 246)
n (%)
Not
colonized
(n = 65)
n (%)
Crude odds ratio (95%
confidence interval)
Male sex 168 (49.6) 31 (40.3) 1.458 (0.882, 2.410) 118 (48.0) 30 (46.2) 1.076 (0.622, 1.861)
Age <24 months 161 (47.5) 41 (53.2) 0.794 (0.484, 1.304) 120 (48.8) 30 (46.2) 1.111 (0.642, 1.922)
Malnutrition
None 171 (50.7) 34 (45.3) 170 (70.3) 43 (69.4)
Mild 86 (25.5) 13 (17.3) 1.315 (0.660, 2.621) 47 (19.4) 15 (24.2) 0.793 (0.405, 1.550)
Moderate 45 (13.4) 17 (22.7) 0.526 (0.270, 1.027) 18 (7.4) 4 (6.4) 1.138 (0.366, 3.537)
Severe 35 (10.4) 11 (14.7) 0.633 (0.293, 1.368) 7 (2.9) 0 (0)
Ever breastfed 307 (93.9) 74 (97.4) 0.415 (0.095, 1.814) 233 (97.9) 60 (96.8) 1.554 (0.294, 8.207)
Currently breastfeeding 78 (24.5) 19 (27.1) 0.869 (0.484, 1.560) 87 (37.3) 19 (30.2) 1.380 (0.757, 2.514)
Current symptoms
Fever 17 (5.0) 3 (4.0) 1.289 (0.368, 4.513) 17 (6.9) 2 (65.0) 2.349 (0.529, 10.436)
Cough 44 (13.0) 6 (7.9) 1.746 (0.716, 4.260) 41 (16.7) 12 (18.5) 0.888 (0.436, 1.807)
Runny nose 147 (43.8) 31 (41.9) 1.079 (0.648, 1.796) 103 (42.2) 21 (32.8) 1.506 (0.843, 2.692)
Hospitalization in past
3 months
46 (13.7) 29 (38.7) 0.252 (0.144, 0.442) 0.364 (0.195, 0.681) 3 (1.3) 0 (0)
Antibiotic use in past 3
weeks
28 (8.4) 18 (24.3) 0.286 (0.148, 0.551) 0.472 (0.224, 0.997) 18 (7.4) 0 (0)
Attends school 10 (3.0) 4 (5.3) 0.555 (0.169, 1.819) 5 (2.1) 1 (1.6) 1.369 (0.157, 11.931)
Smokers in house 38 (12.1) 9 (12.2) 0.994 (0.458, 2.159) 35 (15.0) 11 (17.2) 0.852 (0.405, 1.789)
6 additional persons
living in house
166 (49.6) 38 (50.0) 0.982 (0.597, 1.616) 149 (60.6) 36 (55.4) 1.237 (0.713, 2.149)
Cook with charcoal/
wood
292 (91.3) 72 (97.3) 0.290 (0.067, 1.244) 211 (93.4) 60 (93.75) 0.938 (0.300, 2.931)
Walls made of mud or
sticks
143 (43.3) 34 (44.7) 0.945 (0.572, 1.560) 123 (51.3) 27 (42.86) 1.402 (0.801, 2.453)
HIV exposure — — — 43 (22.3) 9 (19.15) 1.210 (0.543, 2.699)
Antiretroviral therapy 258 (76.1) 57 (74.0) 1.118 (0.634, 1.971) — — —
Cotrimoxazole
prophylaxis
264 (79.0) 66 (86.8) 0.571 (0.279, 1.169) — — —
Site
Manhic¸a 165 (48.7) 30 (39.0) reference — — —
Maputo 92 (27.1) 31 (40.3) 0.540 (0.307, 0.948) — — —
Nampula 82 (24.2) 16 (20.8) 0.932 (0.481, 1.807) — — —
https://doi.org/10.1371/journal.pone.0191113.t002
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colonized with a PCV10 serotype and 49.7% (n = 361) with a PCV13 serotype. The proportion
of children colonized with a vaccine serotype did not significantly vary by HIV status for either
PCV10 (37.5% in HIV-infected, 36.0% among HIV-uninfected; p = 0.681) or for PCV13
(51.7% and 47.0%, respectively; p = 0.206). The proportion colonized with a vaccine serotype
also did not vary significantly by age for either PCV10 (34.9% in <2 year olds, 38.7 in2 year
olds; p = 0.298) or PCV13 (48.6% in <2 year olds, 50.7% in2 year olds; p = 0.574). The pro-
portion colonized with a vaccine serotype was somewhat higher in the northern region (Nam-
pula), compared to other sites; for PCV13 the difference was significant (62.2% in Nampula,
47.7% in other sites; p = 0.007).
A total of 346 isolates were obtained from 339 HIV-infected children with pneumococcal
colonization; 343 (99.1%) underwent antimicrobial susceptibility testing (Table 3). Resistance
to penicillin was <1%. The frequency of intermediate susceptibility to penicillin varied
depending upon the breakpoints used; this proportion was<1% using parenteral (non-menin-
gitis) breakpoints and 65.3% using oral breakpoints. No isolates were resistant to ceftriaxone;
one was resistant to amoxicillin and two were resistant to rifampin. Resistance to trimetho-
prim-sulfamethoxazole was common (88.6%). Among 307 isolates resistant to at least one of
the antibiotics tested, 47.6% (n = 146) were PCV10 serotypes and 66.8% (n = 205) were PCV13
serotypes.
Fig 2. Serotype distribution among nasopharyngeal Streptococcus pneumoniae isolates (n = 601) found among HIV-infected and -uninfected children aged<5
years in Mozambique.
https://doi.org/10.1371/journal.pone.0191113.g002
Table 3. Antibiotic susceptibility among pneumococcal isolates (n = 343) obtained from HIV-infected children.
Antimicrobial agents Susceptible
n (%)
Intermediate
n (%)
Resistant
n (%)
Penicillin, non-meningitis parenteral 340 (99.1) 3 (0.9) 0 (0)
Penicillin, non-meningitis oral 116 (33.8) 224 (65.3) 3 (0.9)
Trimethoprim-Sulfamethoxazole 15 (4.4) 24 (7.0) 304 (88.6)
Ceftriaxone 343 (100.0) 0 (0.0) 0 (0.0)
Amoxicillin 339 (98.8) 3 (0.9) 1 (0.3)
Erythromycin 286 (83.4) 1(0.3) 56 (16.3)
Chloramphenicol 320 (93.3) 0 (0.0) 23 (6.7)
Rifampin 341 (99.4) 0 (0.0) 2 (0.6)
MIC interpretative Criteria according with Clinical and Laboratory Standard Institute (2013).
https://doi.org/10.1371/journal.pone.0191113.t003
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Discussion
We observed high rates of pneumococcal colonization among children aged less than five years
prior to PCV10 introduction in Mozambique, with approximately four out of five children car-
rying at least one pneumococcal serotype. There was remarkably little variation in the preva-
lence of pneumococcal carriage; we found no significant differences between HIV-infected and
-uninfected, between three distinct geographic and epidemiologic contexts, and across age
strata among children less than five years. The most common colonizing serotypes are either
included in PCV10, which was introduced in 2013, or are serotypes against which PCV10 may
provide cross-protection. The serotype coverage of PCV13 (61.7%) was higher than that of
PCV10 (44.9%), primarily because of the inclusion of serotypes 6A and 19A in PCV13. These
data provide useful insight into the potential impact of PCV10 introduction in Mozambique.
The colonization prevalence we observed was higher than that seen in many other African
settings. A recent review of published literature on pneumococcal carriage in sub-Saharan
Africa found an overall prevalence of 63% among children less than five years, with individual
studies reporting a range of 21% to 94%[10]. The broth enrichment used in this study, Todd
Hewitt with the addition of yeast extract and rabbit serum, has been shown to increase the
detection of S. pneumoniae in nasopharyngeal specimens[14]. Concerns have been raised
about potential disadvantages of using broth enrichment, including overgrowth of other spe-
cies and differential rates of growth among different pneumococcal serotypes[17]. However a
recently published study of pneumococcal carriage among children under five years in Kenya
that used the same broth enrichment reported a prevalence of 90% (reflecting 57 pneumococ-
cal serotypes)[15], while other carriage studies from Kenya have found 22% to 74% of children
less than five years to be colonized[18–21]. A previous study of pneumococcal carriage in
Mozambique that did not employ broth enrichment isolated pneumococci from 87% of
enrolled children[22]; however that study was conducted among children attending an outpa-
tient clinic and thus included some with acute respiratory infection, which is a known risk fac-
tor for pneumococcal colonization[23]. In our analysis of risk factors, we did not identify any
variables significantly associated with colonization among HIV-uninfected children; however
the power of the analysis was limited because so few children were not colonized. Among
HIV-infected children, we found that recent antibiotic use and hospitalization within the past
3 months, which may be a proxy for antibiotic use, were protective against colonization. The
prevalence of colonization was lower in Maputo compared with the other two sites; however
after adjusting for recent hospitalization and antibiotic use, there was no significant association
between colonization and study site.
We found no significant difference in the prevalence of colonization by HIV status, in con-
trast to a study in Kenya that reported a significant association between HIV infection and
pneumococcal carriage among children[18]. Furthermore, among HIV-uninfected children,
the proportion colonized was similar among those exposed to HIV in-utero and those born to
HIV-uninfected mothers. Although there were some differences observed in the serotype dis-
tribution among isolates from HIV-infected and–uninfected children, there was no significant
difference in the serotype coverage of available PCVs. HIV is an important risk factor for
pneumococcal disease, with rates of invasive pneumococcal disease among HIV-infected chil-
dren up to 43 times those of HIV-uninfected children[3, 24]. Data on PCV effectiveness
against pneumococcal disease among HIV-infected children are limited[25–27]. If the vaccine
is less protective in HIV-infected children, they might continue to be at high risk for pneumo-
coccal disease, and potentially serve as a reservoir for vaccine serotypes, even after PCV intro-
duction. It is important to monitor PCV impact on carriage and disease in settings with a high
HIV burden as well as to continue to support measures to prevent HIV infections.
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Our data suggest that PCV will have an important impact in Mozambique. The two most
common colonizing serotypes, 19F and 23F, comprise more than a quarter of all colonizing
isolates and are included in both PCV10 and PCV13. Other leading serotypes, such as 6A and
19A, are included in PCV13 but not in PCV10. Immunogenicity data from pre-licensure clini-
cal trials suggested that PCV may provide cross-protection against these serotypes[28, 29].
However, data on PCV10 impact on 6A and 19A carriage and disease are inconclusive. A case-
control study of PCV10 effectiveness against invasive pneumococcal disease in Brazil found
significant protection against serotype 19A[30], and an analysis of incidence trends in Finland
following PCV10 introduction identified significant declines in invasive disease caused by
serotypes 6A and 19A[31]. However, studies from Kenya[21] and Brazil[32] showed no signifi-
cant change in the prevalence of carriage of serotypes 6A and 19A after PCV10 implementa-
tion. A randomized controlled trial in Finland found a significant reduction in carriage of 19A
among children receiving 4 doses of PCV10 (3 primary doses and a booster), but not among
children receiving 3 doses (2 primary doses and a booster)[33]; this same study reported no
impact of PCV10 on carriage of serotype 6A. An ongoing study examining the impact of
PCV10 introduction on carriage in Mozambique will provide addition insight into potential
cross-protection of PCV10 against serotypes 6A and 19A.
Penicillin-resistance among S. pneumoniae has been an increasing global concern since it
was first reported in the late 1960s[34]. In this study, colonizing pneumococcal isolates were
rarely resistant to penicillin or amoxicillin, while the frequency of intermediate susceptibility
to penicillin varied greatly (<1% or 65.3%) depending upon the breakpoints used. Our results
are similar to those of a recent study in Kenya that used oral breakpoints and found that 79%
of colonizing pneumococcal isolates demonstrated intermediate susceptibility to penicillin
and 2.4% were resistant[15]. A review of antimicrobial resistance among S. pneumoniae iso-
lates in Africa reported 25% non-susceptibility to penicillin (using meningitis breakpoints)
and 26% non-susceptibility to ampicillin among colonizing isolates[35]. Our finding of in-
frequent resistance to beta lactams in Mozambique supports the current first line treatment
recommendations for use of beta lactams to treat child pneumonia. However, given the preva-
lence of intermediate penicillin susceptibility using oral breakpoints, continued monitoring
for increased penicillin resistance is warranted. The prevalence of trimethoprim-sulfamethoxa-
zole non-susceptibility in this study (>95%) was higher than that reported by the above-men-
tioned review (47.5%), and similar to the recent study from Kenya (98%). The high level of
trimethoprim-sulfamethoxazole resistance in Mozambique and Kenya likely reflects frequent
use of trimethoprim-sulfamethoxazole for prophylaxis in settings with a high burden of HIV.
This study has several limitations. The HIV-infected participants were selected as a conve-
nience sample of those who attended the HIV clinics for either routine care or management of
an acute illness during the study enrollment period; they may differ from HIV-infected chil-
dren who did not seek care at the clinics. HIV-uninfected children were enrolled from only
one site, Manhic¸a, limiting our ability to generalize results to other areas of Mozambique.
However, among the HIV-infected children, we observed very little variation in pneumococcal
colonization across different geographic regions. Although most of the children in the HIV-
uninfected group had a documented negative HIV test, some were assumed to be uninfected
because they never underwent HIV testing and the threshold for testing infants for HIV in the
study setting is low; it is possible that some children presumed to HIV-uninfected were actu-
ally infected. In addition, for HIV-uninfected children, data on HIV exposure in-utero was
reported by the parent/guardian, which could have resulted in misclassification. Because of
limited resources, antimicrobial susceptibility testing was only performed for colonizing iso-
lates from HIV-infected children. Susceptibility patterns may differ among HIV-uninfected
children. Certain PCV serotypes known to be important causes of invasive disease in
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Mozambique, such as serotypes 1 and 5, are rarely detected in carriage[22]. Thus, descriptions
of the serotype coverage of PCV formulations are an underestimate of the potential impact the
vaccine could have on pneumococcal disease.
This cross-sectional study demonstrated a high prevalence of pneumococcal carriage
among children under the age of five years in Mozambique. Colonization did not vary by age,
geographic region, HIV-infection or HIV exposure. These data can serve as a baseline for eval-
uating PCV10, which was introduced in April 2013. Vaccine impact on carriage in Mozam-
bique will depend on potential cross-protection against serotypes 6A and 19A, and the impact
against disease will depend on vaccine effectiveness against serotypes not reflected in carriage
data (serotypes 1 and 5). Our ongoing work to evaluate PCV10 impact on carriage, pneumonia
and invasive disease will help address questions about PCV performance in high-HIV preva-
lence settings with a high burden of pneumococcal disease.
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